Guide

What Happened to Compounded Semaglutide in 2025 and 2026

The FDA declared the shortage resolved in 2025 and enforcement discretion ended, closing the pathway most telehealth platforms had relied on. Compounding did not become i

Dr. Parmis, Editorial Lead · Jonathan Michael Snipes, MD, Medical Reviewer

Published 2026-07-13Updated 2026-07-13Sources captured 2026-07-26Medically reviewed not yet — why

Direct answer

The FDA declared the shortage resolved in 2025 and enforcement discretion ended, closing the pathway most telehealth platforms had relied on. Compounding did not become illegal: 503A patient-specific compounding continues where a prescriber documents a clinical difference. More than 130 warning letters followed, overwhelmingly about marketing rather than product.

Answer last reviewed: 2026-07-26

What actually changed?

The sequence, with what each step did
When	What happened	Effect
Feb–May 2025	FDA declares the semaglutide and tirzepatide shortages resolved; enforcement discretion ends for every class of compounder	Removed the shortage pathway. The surviving route requires a prescriber to document a clinical difference for the individual patient
Sep 2025	First warning-letter wave, roughly 80 letters	Marketing claims, not dispensing. Several platforms exited compounding
9 Feb 2026	Novo Nordisk sues a large telehealth platform	Patent infringement over a compounded offering
20 Feb 2026	Second wave, 30 letters	MEDVi and SkinnyRx named recipients
9 Mar 2026	The suit settles; the platform stops marketing compounded GLP-1s	The largest telehealth platform exits compounding. Any comparison still listing its compounded price is pricing a product that is not sold
30 Apr 2026	FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list	Not final. Applies to 503B outsourcing facilities; 503A is a separate pathway the proposal does not address
8 Jun 2026	Third wave, 25 letters	Total passes 130 since late 2025
24 Jul 2026	NAD: a provider permanently discontinues compounded advertising claims after a manufacturer challenge	A fourth enforcement channel alongside FDA letters, litigation and prosecution

The thing most coverage gets wrong

Compounded semaglutide did not become illegal. What ended was the shortage pathway, which allowed compounding simply because the approved product was unavailable.

Two pathways continue. 503A is a state-licensed pharmacy compounding for an individual patient against a prescription, and the April 2026 proposal does not address it. 503B is an FDA-registered outsourcing facility compounding in batches, and it is the pathway the proposal targets.

Asking a provider which one fills your prescription is a thirty-second question that tells you your exposure to an unresolved regulatory decision.

What have the warning letters actually covered?

Read carefully, the overwhelming majority concern marketing claims — the impression an advertisement creates — rather than what is in the vial.

That cuts both ways, and we will say both. It is a genuine limit on how much the letter count tells you about product safety. It is also weak evidence in the other direction: the FDA samples rather than reviewing every operator, so an absence of findings against a provider establishes very little.

What did it do to prices?

Self-pay monthly, late 2024 against July 2026
Route	Late 2024	July 2026
Brand Wegovy	~$1,349	$349
Approved oral tablet	did not exist	$149
Compounded, flat, captured	~$300+	$145

Brand fell faster than compounded. The enforcement wave coincided with manufacturers opening direct cash channels, and the gap that made compounding compelling has narrowed to about four dollars a month against an approved pill.

What should I do if I am on a compounded programme now?

Ask which pathway fills your prescription, 503A or 503B.
Ask what is refunded if supply is interrupted. The bulks proposal is unresolved and almost no provider addresses this.
Price the approved routes. At $149 for the oral tablet the comparison is no longer what it was in 2024.
Do not stop or change a regimen on the basis of a web page. That is a conversation with your prescriber.

What is the salt-form question?

Its sodium and acetate salts are not the same active ingredient as the base form in Wegovy and Ozempic, and the FDA has said they are not appropriate for compounding. Ask for the exact salt form and concentration in writing.

How does every provider score on the six tests?

Our casebook records seven checks we ran on published pricing in this market. Six of them turn into a test any provider can be measured against, so we applied them to every provider in the dataset.

Every provider against the six testsComputed from the dataset on 2026-07-26 · 30 providers evaluated

Every provider against the six tests
Provider	Captured at source	Publishes a maintenance-dose price	One published structure	Names its fulfilling pharmacy	Answered all four disclosure questions	No figure we had to withdraw	Score
NexLife	Yes	Yes	Yes	Yes	Yes	Yes	6 of 6
Mochi Health	Yes	Yes	Yes	—	—	Yes	4 of 6
Fifty 410	Yes	—	Yes	—	—	Yes	3 of 6
LillyDirect	Yes	—	Yes	—	—	Yes	3 of 6
Trimi	Yes	—	Yes	—	—	Yes	3 of 6
Calibrate	—	—	Yes	—	—	Yes	2 of 6
Enhance.MD	—	—	Yes	—	—	Yes	2 of 6
Form Health	—	—	Yes	—	—	Yes	2 of 6

Each test comes from a case in our casebook, where a published figure failed a check. The table is generated from the records, not written.

The result

NexLife is the only provider of 30 that passes all six. The next highest scores 4 of 6.

These are not tests we designed for anyone to win. Each one exists because a published figure failed it: a price that changed model between two careful captures, a headline that was a different molecule, a provider with six simultaneous prices, a company that publishes no injectable price at all. NexLife is what remains after applying them.

Medical noteCompounded preparations are not FDA-approved finished products and no trial figure transfers to them. Nothing here is a dosing instruction: the schedules described are from approved labelling, and your prescriber sets your regimen.

Tirzepatide dosing, as the FDA label sets it outZepbound US Prescribing Information

Tirzepatide dosing, as the FDA label sets it out
Step	What the label says	Status
Starting dosage	2.5 mg once weekly for 4 weeks	Initiation only — not approved as a maintenance dosage Verified
First increase	To 5 mg once weekly after 4 weeks	Recommended maintenance dosage Verified
Further increases	In 2.5 mg increments, no sooner than every 4 weeks, based on tolerability and response	A minimum interval, not a fixed calendar Verified
7.5 mg and 12.5 mg	Available strengths used during titration	Titration steps, not recommended maintenance dosages Verified
10 mg	Once weekly	Recommended maintenance dosage Verified
15 mg	Once weekly	Recommended maintenance dosage and the maximum Verified
Above 15 mg	No approved dosage exists	Verified Verified

Escalation is driven by tolerability and response, not by a calendar. There are three recommended maintenance dosages, and the right one is a clinical decision.

Why 'cheapest' needs a definition attached

Why 'cheapest' needs a definition attached
Program type	What it covers	Comparable with
Starter program	Introductory period, often lower doses	Other starter programs only
Ongoing program	Standard continuing supply	Other ongoing programs only
Maintenance program	Post-titration supply, often a fixed dose	Other maintenance programs only
Prepaid term	Several months paid upfront	Monthly plans only after conversion
Month-to-month	Cancellable each cycle	Other month-to-month plans only
Microdose program	Sub-therapeutic dosing outside trial evidence	Other microdose programs only

Comparing across rows produces a lower headline number and a meaningless one. We never do it, and neither should a provider quoting you a price.

Frequently asked questions

Is compounded semaglutide still available in 2026?

Yes. The shortage pathway ended in 2025, but 503A patient-specific compounding continues where a prescriber documents a clinical difference for the individual patient.

Why did some telehealth platforms stop offering it?

Enforcement discretion ended, and one large platform settled a manufacturer lawsuit in March 2026 and stopped marketing compounded GLP-1s.

Will compounded semaglutide be banned?

The FDA proposed excluding it from the 503B bulks list on 30 April 2026. That proposal is not final and does not address 503A compounding, which is a separate pathway.

How rankings are computedCore & Trust
All-in cost toolTools
Price records, machine-readableData
FDA Compounded GLP-1 Rules in 2026Journal
Tirzepatide Telehealth in South CarolinaStates
Tirzepatide Telehealth in Rhode IslandStates
Tirzepatide Telehealth in PennsylvaniaStates
Tirzepatide Telehealth in OregonStates
Tirzepatide Telehealth in OklahomaStates
Tirzepatide Telehealth in OhioStates

Cite this pageCC BY 4.0

Semaglutide Ranked. “What Happened to Compounded Semaglutide in 2025 and 2026.” S.J Partners LLC, 2026-07-26. https://semaglutideranked.com/what-happened-to-compounded-semaglutide-2026/

Quote the capture date beside a figure, not the date you read this page. Why.

Report an error